Lipodystrophies in Children

Background: Lipodystrophy includes a wide group of diseases characterized by reduction, absence, or altered distribution of adipose tissue. Lipodystrophies are classified into generalized or partial, according to the fat distribution, and congenital or acquired, considering the etiology. Summary: Impaired glucose and lipid metabolism are typically present, thus severe insulin resistance, diabetes mellitus, dyslipidemia, and hepatic steatosis are frequent complications. Because of the rarity and the diversification of lipodystrophies, diagnosis might be challenging, typically for partial forms that cannot be easily recognized, leading to progression of the several metabolic abnormalities associated. First management of lipodystrophy is diet and lifestyle changes, followed by the treatment of metabolic complications. Replacement therapy with metreleptin, currently available in the USA and Europe, has shown improvement of metabolic profile in a great number of patients with lipodystrophy. Key Messages: The purpose of this review was to describe the phenotypic characteristics of all the known lipodystrophic types and to present specific steps for obtaining an early diagnosis and assessing the best treatment of lipodystrophy.

[1]  B. Donadille,et al.  Molecular and Cellular Bases of Lipodystrophy Syndromes , 2022, Frontiers in Endocrinology.

[2]  F. Santini,et al.  Autoimmunity in lipodystrophy syndromes. , 2021, Presse medicale.

[3]  T. Kusakabe,et al.  Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES). , 2021, Endocrine journal.

[4]  C. Mantzoros,et al.  Severe insulin resistance syndromes. , 2021, The Journal of clinical investigation.

[5]  B. Knebel,et al.  Lipodystrophies—Disorders of the Fatty Tissue , 2020, International journal of molecular sciences.

[6]  E. Helfer,et al.  Molecular and Mechanobiological Pathways Related to the Physiopathology of FPLD2 , 2020, Cells.

[7]  A. Bargiota,et al.  Familial Partial Lipodystrophy (FPLD): Recent Insights , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[8]  Yingying Luo,et al.  Diagnostic strategies and clinical management of lipodystrophy , 2020, Expert review of endocrinology & metabolism.

[9]  B. Akıncı,et al.  Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People , 2020, Journal of clinical research in pediatric endocrinology.

[10]  C. Vigouroux,et al.  Lipodystrophic syndromes: From diagnosis to treatment. , 2019, Annales d'endocrinologie.

[11]  Feng-Jung Chen,et al.  CIDE family proteins control lipid homeostasis and the development of metabolic diseases , 2019, Traffic.

[12]  C. Vigouroux,et al.  Diagnostic Challenge in PLIN1-Associated Familial Partial Lipodystrophy , 2019, The Journal of clinical endocrinology and metabolism.

[13]  D. Savage,et al.  Recent developments in lipodystrophy. , 2019, Current opinion in lipidology.

[14]  E. Kalkhoven,et al.  Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPARγ mutants. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[15]  E. Deeks Metreleptin in lipodystrophy: a profile of its use , 2019, Drugs & Therapy Perspectives.

[16]  V. Saudek,et al.  Dual binding motifs underpin the hierarchical association of perilipins1–3 with lipid droplets , 2019, Molecular biology of the cell.

[17]  M. Weedon,et al.  PLIN1 Haploinsufficiency Is Not Associated With Lipodystrophy , 2018, The Journal of clinical endocrinology and metabolism.

[18]  S. O’Rahilly,et al.  Genetic syndromes of severe insulin resistance. , 2018, Current opinion in genetics & development.

[19]  F. Santini,et al.  Diagnosis and treatment of lipodystrophy: a step-by-step approach , 2018, Journal of Endocrinological Investigation.

[20]  J. Seissler,et al.  Insulin secretory defect in familial partial lipodystrophy Type 2 and successful long‐term treatment with a glucagon‐like peptide 1 receptor agonist , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[21]  C. Mantzoros,et al.  Adipose tissue and reproductive health. , 2017, Metabolism: clinical and experimental.

[22]  E. Chiquette,et al.  Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges , 2017, Diabetes, metabolic syndrome and obesity : targets and therapy.

[23]  Robert V Farese,et al.  Lipid Droplet Biogenesis. , 2017, Annual review of cell and developmental biology.

[24]  F. Rubino,et al.  Roux-en-Y Gastric Bypass Surgery in the Management of Familial Partial Lipodystrophy Type 1 , 2017, The Journal of clinical endocrinology and metabolism.

[25]  A. Tsatsoulis,et al.  Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation , 2017, Endocrinology, diabetes & metabolism case reports.

[26]  K. Muroya,et al.  Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey , 2017, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[27]  M. Kroh,et al.  Successful Treatment of an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass—Case Report and Literature Review , 2017, Journal of Gastrointestinal Surgery.

[28]  F. Karpe,et al.  What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? , 2017, International Journal of Obesity.

[29]  A. Garg,et al.  Homozygous LIPE mutation in siblings with multiple symmetric lipomatosis, partial lipodystrophy, and myopathy , 2017, American journal of medical genetics. Part A.

[30]  Inês Barroso,et al.  Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance , 2016, Nature Genetics.

[31]  D. Dunger,et al.  The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline , 2016, The Journal of clinical endocrinology and metabolism.

[32]  E. Oral,et al.  Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program , 2016, Journal of diabetes & metabolism.

[33]  E. Jaffe,et al.  Lymphoma in acquired generalized lipodystrophy , 2016, Leukemia & lymphoma.

[34]  N. Patni,et al.  Congenital generalized lipodystrophies—new insights into metabolic dysfunction , 2015, Nature Reviews Endocrinology.

[35]  T. Atik,et al.  Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. , 2015, Metabolism: clinical and experimental.

[36]  V. Cortés,et al.  Lipodystrophies: adipose tissue disorders with severe metabolic implications , 2015, Journal of Physiology and Biochemistry.

[37]  C. Vigouroux,et al.  Metabolic and cardiac phenotype characterization in 37 atypical Dunnigan patients with nonfarnesylated mutated prelamin A. , 2015, American heart journal.

[38]  P. Gorden,et al.  Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. , 2015, The Journal of clinical endocrinology and metabolism.

[39]  Q. Gao,et al.  Seipin performs dissectible functions in promoting lipid droplet biogenesis and regulating droplet morphology , 2015, Molecular biology of the cell.

[40]  M. Glesby,et al.  HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings , 2015, Journal of the International AIDS Society.

[41]  E. Ravussin,et al.  Caveolin-1 Expression and Cavin Stability Regulate Caveolae Dynamics in Adipocyte Lipid Store Fluctuation , 2014, Diabetes.

[42]  J. Moreno-Navarrete,et al.  Polymerase I and transcript release factor (PTRF) regulates adipocyte differentiation and determines adipose tissue expandability , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  K. Rother,et al.  Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. , 2014, The Journal of clinical endocrinology and metabolism.

[44]  S. Baig,et al.  Exome sequencing circumvents missing clinical data and identifies a BSCL2 mutation in congenital lipodystrophy , 2014, BMC Medical Genetics.

[45]  Jeffrey R O'Connell,et al.  Null mutation in hormone-sensitive lipase gene and risk of type 2 diabetes. , 2014, The New England journal of medicine.

[46]  A. Ciccodicola,et al.  PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms , 2014, PPAR research.

[47]  Y. Sakamoto,et al.  Severe congenital lipodystrophy and a progeroid appearance: Mutation in the penultimate exon of FBN1 causing a recognizable phenotype , 2013, American journal of medical genetics. Part A.

[48]  T. Nolis Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies , 2013, Journal of Human Genetics.

[49]  D. Carvalho,et al.  Lipodystrophy: beyond generalization? , 2013, Panminerva medica.

[50]  Sahar Mansour,et al.  Mutations in PIK3R1 cause SHORT syndrome. , 2013, American journal of human genetics.

[51]  Stefan Johansson,et al.  SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. , 2013, American journal of human genetics.

[52]  Patrick Callier,et al.  PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. , 2013, American journal of human genetics.

[53]  B. Venkatesh,et al.  Seipin differentially regulates lipogenesis and adipogenesis through a conserved core sequence and an evolutionarily acquired C-terminus. , 2013, The Biochemical journal.

[54]  J. Chan,et al.  The clinical approach to the detection of lipodystrophy - an AACE consensus statement. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[55]  Charles R. Evans,et al.  Alterations in lipid signaling underlie lipodystrophy secondary to AGPAT2 mutations. Diabetes 2012;61:2922–2931 , 2013, Diabetes.

[56]  S. O’Rahilly,et al.  The human lipodystrophy protein seipin is an ER membrane adaptor for the adipogenic PA phosphatase lipin 1. , 2013, Molecular metabolism.

[57]  Charles R. Evans,et al.  Alterations in Lipid Signaling Underlie Lipodystrophy Secondary to AGPAT2 Mutations , 2012, Diabetes.

[58]  R. Payne Cardiovascular risk. , 2012, British journal of clinical pharmacology.

[59]  A. Agarwal Lysophospholipid acyltransferases: 1-acylglycerol-3-phosphate O-acyltransferases. From discovery to disease , 2012, Current opinion in lipidology.

[60]  J. Goodman,et al.  Seipin: from human disease to molecular mechanism , 2012, Journal of Lipid Research.

[61]  P. Gorden,et al.  Pregnancy in a Woman With Congenital Generalized Lipodystrophy: Leptin's Vital Role in Reproduction , 2012, Obstetrics and gynecology.

[62]  J. Chan,et al.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[63]  A. Lecube,et al.  Successful treatment for the Dunnigan‐type familial partial lipodystrophy with Roux‐en‐Y gastric bypass , 2011, Clinical endocrinology.

[64]  C. Vigouroux,et al.  Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. , 2011, The international journal of biochemistry & cell biology.

[65]  S. O’Rahilly,et al.  Perilipin deficiency and autosomal dominant partial lipodystrophy. , 2011, The New England journal of medicine.

[66]  S. O’Rahilly,et al.  Lipodystrophy: metabolic insights from a rare disorder. , 2010, The Journal of endocrinology.

[67]  M. Delgado,et al.  Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations , 2010, American journal of medical genetics. Part A.

[68]  J. Chan,et al.  Clinical classification and treatment of congenital and acquired lipodystrophy. , 2010, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[69]  D. Seelow,et al.  Fatal Cardiac Arrhythmia and Long-QT Syndrome in a New Form of Congenital Generalized Lipodystrophy with Muscle Rippling (CGL4) Due to PTRF-CAVIN Mutations , 2010, PLoS genetics.

[70]  L. Subramanyam,et al.  Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino‐terminal heterozygous missense lamin A/C mutations , 2009, Clinical genetics.

[71]  S. Bernasconi,et al.  Mandibuloacral dysplasia type A in childhood , 2009, American journal of medical genetics. Part A.

[72]  Cristina T Fonseca,et al.  Novel mutations of the BSCL2 and AGPAT2 genes in 10 families with Berardinelli–Seip congenital generalized lipodystrophy syndrome , 2009, Clinical endocrinology.

[73]  A. Garg,et al.  Inherited lipodystrophies and hypertriglyceridemia , 2009, Current opinion in lipidology.

[74]  S. O’Rahilly,et al.  Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC , 2009, EMBO molecular medicine.

[75]  L. Tavazzi,et al.  Long-term outcome and risk stratification in dilated cardiolaminopathies. , 2008, Journal of the American College of Cardiology.

[76]  A. K. Agarwal,et al.  Novel subtype of congenital generalized lipodystrophy associated with muscular weakness and cervical spine instability , 2008, American journal of medical genetics. Part A.

[77]  S. O’Rahilly,et al.  The Human Lipodystrophy Gene BSCL2/Seipin May Be Essential for Normal Adipocyte Differentiation , 2008, Diabetes.

[78]  S. O’Rahilly,et al.  Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. , 2008, The Journal of clinical endocrinology and metabolism.

[79]  P. Pilch,et al.  A Critical Role of Cavin (Polymerase I and Transcript Release Factor) in Caveolae Formation and Organization* , 2008, Journal of Biological Chemistry.

[80]  S. Kanazawa,et al.  Computed tomography findings of congenital generalized lipodystrophy: multiple nodular fatty liver and diffuse sclerosis of bones , 2007, Radiation Medicine.

[81]  R. Parton,et al.  The multiple faces of caveolae , 2007, Nature Reviews Molecular Cell Biology.

[82]  Xianlin Han,et al.  A Regulatory Role for 1-Acylglycerol-3-phosphate-O-acyltransferase 2 in Adipocyte Differentiation* , 2006, Journal of Biological Chemistry.

[83]  J. Pinkney,et al.  Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C , 2005, Diabetologia.

[84]  G. Behrens Cardiovascular risk and body-fat abnormalities in HIV-infected adults. , 2005, The New England journal of medicine.

[85]  P. Vermersch,et al.  Patients with familial partial lipodystrophy of the Dunnigan type due to a LMNA R482W mutation show muscular and cardiac abnormalities. , 2004, The Journal of clinical endocrinology and metabolism.

[86]  S. O’Rahilly,et al.  Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. , 2004, The Journal of clinical endocrinology and metabolism.

[87]  A. Kimmel,et al.  The Central Role of Perilipin A in Lipid Metabolism and Adipocyte Lipolysis , 2004, IUBMB life.

[88]  A. Garg Acquired and inherited lipodystrophies. , 2004, The New England journal of medicine.

[89]  A. Garg,et al.  Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature , 2004, Medicine.

[90]  A. Garg,et al.  Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. , 2003, The Journal of clinical endocrinology and metabolism.

[91]  A. K. Agarwal,et al.  Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. , 2003, Human molecular genetics.

[92]  A. Garg,et al.  Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways , 2003, Trends in Endocrinology & Metabolism.

[93]  A. Chait,et al.  Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. , 2003, Diabetes care.

[94]  Laura Scott,et al.  Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome , 2003, Nature.

[95]  A. Garg,et al.  Clinical Features and Metabolic Derangements in Acquired Generalized Lipodystrophy: Case Reports and Review of the Literature , 2003, Medicine.

[96]  A. Garg,et al.  Lipodystrophy in Human Immunodeficiency Virus-Infected Patients , 2002 .

[97]  S. O’Rahilly,et al.  Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy , 2002, Journal of medical genetics.

[98]  G. Scarano,et al.  Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. , 2002, American journal of human genetics.

[99]  M. Serrano-Ríos,et al.  Leptin and Adipose Tissue Maldistribution in HIV‐Infected Male Patients With Predominant Fat Loss Treated With Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.

[100]  J. Engelman,et al.  Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) , 1998, FEBS letters.

[101]  S. O’Rahilly,et al.  Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly. A disorder characterized by selective postreceptor insulin resistance. , 1998, The Journal of clinical investigation.

[102]  O. Trygstad,et al.  Generalized lipodystrophy, congenital and acquired (lipoatrophy) , 1996, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[103]  J. Köbberling,et al.  Familial partial lipodystrophy: two types of an X linked dominant syndrome, lethal in the hemizygous state. , 1986, Journal of medical genetics.

[104]  M. Seip Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? , 1959, Acta paediatrica.

[105]  W. Berardinelli An undiagnosed endocrinometabolic syndrome: report of 2 cases. , 1954, The Journal of clinical endocrinology and metabolism.

[106]  M. Kurusz,et al.  Efficacy and safety , 2021, Perfusion.

[107]  A. Garg,et al.  Lipodystrophy Syndromes. , 2016, Endocrinology and metabolism clinics of North America.

[108]  C. Mantzoros,et al.  Leptin in congenital and HIV-associated lipodystrophy. , 2015, Metabolism: clinical and experimental.

[109]  C. Mantzoros,et al.  From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. , 2015, Metabolism: clinical and experimental.

[110]  A. Garg Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[111]  E. Mesquita,et al.  [Cardiometabolic abnormalities in patients with Berardinelli-Seip syndrome]. , 2010, Arquivos brasileiros de cardiologia.

[112]  Kenneth G. C. Smith,et al.  Complement abnormalities in acquired lipodystrophy revisited. , 2009, The Journal of clinical endocrinology and metabolism.

[113]  N. Maraldi,et al.  Implications for nuclear organization and gene transcription of lamin A/C specific mutations. , 2005, Advances in enzyme regulation.

[114]  A. Bowcock,et al.  AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34 , 2002, Nature Genetics.

[115]  A. Garg,et al.  A Novel Heterozygous Mutation in Peroxisome Proliferator-Activated Receptor-γ Gene in a Patient with Familial Partial Lipodystrophy , 2002 .

[116]  R. Hegele,et al.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. , 2000, Human molecular genetics.

[117]  R. Peshock,et al.  Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). , 1999, The Journal of clinical endocrinology and metabolism.